Integrum invites to Open House Event to celebrate its 25-year anniversary
Mölndal, Sweden – June 1, 2023 — Integrum (publ) (Nasdaq First North Growth Market: INTEG B) will host an Open House Event on June 15 to inaugurate the company’s new headquarters at GoCO Health Innovation City and celebrate its 25th anniversary.
Integrum was founded in 1998, and over the 25 years, groundbreaking technologies have continuously been developed. For instance, more than 10 years ago, on January 29, 2013, in a patient already using the OPRATM Implant System, electrodes were implanted to improve motor control and create artificial sensory feedback using artificial intelligence. In April 2023, Integrum moved to the company’s new headquarters. The successes achieved in the first 25 years will be celebrated during an Open House Event on June 15.
During the event, experts from Integrum and patients will present what has been made possible thanks to the company’s life-changing innovations. Integrum’s CEO and founder, Rickard Brånemark, will inaugurate the new headquarters, give a short presentation of achieved milestones, and report on his recent engagements.
The Open House Event will be held on June 15, at 15.00-18.00.
Address: Entreprenörsstråket 10, Mölndal
Food and drinks will be served.
To attend, register here before June 10.
For more information please contact:
Rickard Brånemark, CEO
Phone: +46 (0) 70 846 10 61
E-mail: rickard.branemark@integrum.se
Certified Adviser
Erik Penser Bank is Certified Adviser.
ABOUT INTEGRUM
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.